Search the Newsreel

Farmmi shares fall below $1, faces Nasdaq compliance deadline by Feb 2027 to avoid delisting

Farmmi, Inc. has received a Nasdaq notice because its shares have closed below $1 for 30 consecutive business days. The company has until February 8, 2027, to regain compliance by increasing its share price above $1 for 10 consecutive days or by performing a …

5 Revealing Analyst Questions From Cummins’s Q2 Earnings Call

5 Revealing Analyst Questions From Cummins's Q2 Earnings Call Cummins' second quarter was marked by robust top-line growth, but profitability faced headwinds, leading to a negative market reaction. Management highlighted surging power generation demand—especially from data centers—as a significant driver, with CEO Jennifer Rumsey …

Farmmi (FAMI) flagged for Nasdaq bid price rule, issues 1.58M shares to Atlas

Farmmi, Inc. (FAMI) has been notified by Nasdaq for failing to meet the $1.00 minimum bid price requirement for 30 consecutive business days. The company has a 180-day compliance period until February 8, 2027, to regain compliance, with the possibility of a second 180-day …

Farmmi receives Nasdaq minimum bid price deficiency notice By Investing.com

Farmmi Inc. (NASDAQ:FAMI) has received a notification from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until February 8, 2027, to regain compliance, potentially through a reverse …

Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside

Summit Therapeutics Inc.'s average 12-month price target has been lowered to $28.34 from $29.52 by 14 analysts, yet this new target still suggests an 88% upside from its Aug. 11 closing price. The consensus rating for the stock remains a "Buy" among 18 analysts.

Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab

Summit Therapeutics (SMMT) shares rose after China's National Medical Products Administration approved a label expansion for its bispecific antibody ivonescimab, allowing its first-line use with chemotherapy for advanced squamous non-small cell lung cancer. Despite an extremely high price-to-sales ratio and ongoing losses, insider purchases …

Marcus & Millichap Negotiates Sale of Baybury Square Shopping Center Portfolio in Metro Dallas

Marcus & Millichap has successfully negotiated the sale of the Baybury Square Shopping Center portfolio in Richardson, Texas. The 51,542-square-foot retail property, consisting of two multi-tenant centers and two freestanding buildings, was approximately 64 percent leased at the time of sale. A local real …

Schroder Investment Group (MMI) discloses 6.0% Marcus & Millichap ownership stake

Schroder Investment Management Group has reported a beneficial ownership stake of 6.0% in Marcus & Millichap Inc. (MMI), totaling 2,285,406 shares. This includes sole voting and dispositive power over 362,413 shares. The ownership is distributed among affiliated entities, with Schroder Investment Management Limited holding …

Marcus & Millichap Arranges $2.4M Multifamily Sale in Quincy Massachusetts

Marcus & Millichap has successfully arranged the sale of The Residences at Des Moines Road, a seven-unit multifamily property in Quincy, Massachusetts, for $2.4 million. The property, built in 2005, attracted significant interest due to its modern features and was ultimately sold to an …

Summit higher as partner Akeso wins China label expansion for lead drug

[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansion for the company’s lead drug, ivonescimab, developed with Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]). * According to Summit …

Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC

Summit Therapeutics announced that its partner Akeso has received approval in China for ivonescimab for use in squamous non-small cell lung cancer (NSCLC). This approval marks a significant milestone for the bispecific antibody, which combines immunotherapy and anti-angiogenesis effects. Ivonescimab is also being developed …

Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners

Leerink Partners upgraded Summit Therapeutics (NASDAQ:SMMT) from "underperform" to "market perform" with a $13 price target. The company currently holds an average "Hold" rating from analysts with an average price target of $24.25, and recently reported quarterly EPS of -$0.28, missing estimates. Insider buying …

Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright

HC Wainwright has lowered its Q3 2026 EPS estimate for Immix Biopharma (NASDAQ:IMMX) to a loss of $0.17 per share, down from a previous forecast of $0.14 loss, while maintaining a "Buy" rating and a $25 price target. This revision follows Immix Biopharma reporting …

Dimensional Fund Advisors LP Sells 200,688 Shares of Summit Hotel Properties, Inc. $INN

Dimensional Fund Advisors LP reduced its stake in Summit Hotel Properties (NYSE:INN) by 13.3% in the first quarter, selling 200,688 shares but still holding 1.31 million shares valued at $5.77 million. The REIT reported stronger-than-expected Q1 earnings of $0.04 EPS and revenue of $199.02 …

Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?

5 Revealing Analyst Questions From Marcus & Millichap’s Q2 Earnings Call

Key Points Interested in Marcus & Millichap, Inc.? Here are five stocks we like better. Strong Q2 recovery: Revenue rose 18% to $203 million, while net income improved to $4 million from an $11 million loss a year earlier. Adjusted EBITDA increased to $12 …

Summit Midstream Corp (SMC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Shimmick (SHIM) Stock Price Drops As Margin Recovery Meets Cash Strain

UBS Group AG Reduces Stake in Summit Hotel Properties Inc (INN) by 32%

UBS Group AG has reduced its stake in Summit Hotel Properties Inc (INN) by 31.97%, selling over 4.1 million shares. Despite this significant reduction, INN represents only 0.01% of UBS's total portfolio. Summit Hotel Properties is a REIT focusing on upscale select-service hotels, currently …

Summit Midstream (SMC) Stock Jumps On Profit Turn As Cash Flow Draws Focus

Summit Midstream (SMC) stock rose 8.9% after reporting a shift from a loss to a small profit in Q2 2026, driven by strong operating cash flow. The company's adjusted earnings per share reached US$0.33, and adjusted EBITDA hit US$60.7 million, indicating a positive turn …

Earnings call transcript: Summit Midstream beats Q2 2026 estimates, lifts outlook

Summit Midstream Corp. reported stronger-than-expected Q2 2026 results, with adjusted earnings and revenue surpassing analyst estimates due to increased volumes in the Rockies and Mid-Con segments. The company raised its full-year adjusted EBITDA guidance to $235 million-$255 million and saw its shares climb in …

Summit Midstream Partners Q2 Earnings Call Highlights

Marcus & Millichap Brokers $16.5M Sale of Two Student Housing Assets in Clemson South Carolina

Marcus & Millichap has successfully brokered the $16.5 million sale of two student housing properties, The Den at Clemson East and The Den at Clemson West, located in Clemson, South Carolina. These properties, totaling 146 units, were acquired by a South Carolina-based buyer from …

Cummins (CMI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11 a.m. ET CALL PARTICIPANTS Executive Director of Investor Relations - Nicholas Arens Chair and Chief Executive Officer - Jennifer Rumsey Executive Vice President and Chief Financial Officer - Mark Smith Full Conference …

Summit Midstream keeps common dividend suspended, declares Series A preferred payout

* Summit Midstream (SMC [https://seekingalpha.com/symbol/SMC]) that its Board continued to suspend cash dividends payable on the common stock for the period ended June 30, 2026. * The quarterly cash dividend on the Series A Preferred Stock, for the period ended Sep 14, 2026, will …

Summit Midstream Partners (NYSE:SMC) Trading Up 6.1% Following Earnings Beat

Summit Midstream Partners (NYSE:SMC) saw its shares rise by 6.1% after reporting a quarterly EPS of $0.11, significantly beating the analyst estimate of a $0.36 loss, despite revenue falling short of forecasts. The company also announced a $35 million stock buyback program, allowing the …

Marcus & Millichap brokers $7M sale of mixed-use property in Livingston near Route 10 Circle

Marcus & Millichap has brokered the sale of a 26,240-square-foot mixed-use retail center in Livingston, New Jersey, for $7.05 million. The property, located at 107 E. Mount Pleasant Ave., was 92% occupied at the time of sale and includes retail and office suites, along …

Latham & Watkins Advises Summit Hotel Properties in US$200 Million At-the-Market Program

Latham & Watkins LLP advised Summit Hotel Properties, Inc. (NYSE: INN) in its US$200 million at-the-market equity program. The real estate investment trust will offer and sell shares of its common stock. A Latham & Watkins team led by partners Mollie Duckworth, Jonathan Sarna, …

Marcus & Millichap Arranges $5 Million Sale of Single-Tenant Retail Property in Alameda, California

Marcus & Millichap has facilitated the $5 million sale of a single-tenant retail property in Alameda, California. The 3,000-square-foot building is occupied by Peet’s Coffee & Tea under a 10-year lease with annual rent increases. A California-based private corporate trust acquired the property, while …

HC Wainwright Estimates Immix Biopharma FY2027 Earnings

HC Wainwright forecasts Immix Biopharma (NASDAQ: IMMX) to report a loss of $0.20 per share for FY2027, maintaining a "Buy" rating and a $25 price target. This contrasts with the current consensus estimate of a $0.69 loss per share. The company recently reported a …

Hunton Advises on Summit Hotel Properties, Inc.’s $200M ATM

Hunton Andrews Kurth LLP represented the sales agents for Summit Hotel Properties, Inc.'s $200 million common stock at-the-market (ATM) offering program. Summit Hotel Properties, Inc. (NYSE: INN) is a real estate investment trust focused on premium-branded lodging facilities. The Hunton team included partners Rob …

Marcus & Millichap Capital secures $9.79 million for 13,575 s/f mixed-use

Marcus & Millichap Capital Corp. (MMCC) has secured $9.79 million in financing for the acquisition of a 13,575 sq ft mixed-use property in Brooklyn, NY. The financing was a five-year, fixed-rate non-recourse loan with interest-only payments for five years at 60% loan-to-value. The property …

Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis

Immix Biopharma has published a corporate presentation detailing its lead program, NXC-201 BCMA CAR-T, for relapsed or refractory AL amyloidosis. The presentation highlights a 95% complete response rate for NXC-201 from its NEXICART-2 U.S. phase 1/2 trial, which has completed enrollment with 45 patients. …

Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside

Immix Biopharma, Inc. (IMMX) has seen its average 12-month price target adjusted down slightly from $20.56 to $20.44 by 8 analysts. Despite the minor cut, the new target still implies a significant 102% potential upside from its Aug. 10 closing price. The consensus rating …

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

Morgan Stanley has adjusted its price target for Immix Biopharma (IMMX) to $19, down from $20, while maintaining an Overweight rating on the stock. This update comes after the company recently reported its earnings results for the second quarter and six months ended June …

Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates